Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Non-alcoholic steatohepatitis (NASH) is a hepatic manifestation of metabolic syndrome that can progress to liver cirrhosis.
We have established a NASH animal model with higher face validity qualities and that we believe is more clinically translatable than other popular models . Our NASH model exhibits pronounced obesity, dyslipidemia, insulin resistance, accompanied by liver steatosis, inflammation, fibrosis and hepatic triglyceride content . In this way, we believe that this model closely mimics most features of human NASH and may represent the most relevant rodent model of NASH.
Importantly, we have validated this model with the PPAR alpha agonist fenofibrate, and the clinical proven NASH candidate, obeticholic acid (OCA; an FXR agonist).
Below are data comparing a standard diet (SD) with our modified diet (MD)-treated animals on vehicle, fenofibrate or OCA (N=9-12).
Based upon these results, we conclude that the modified high fat diet model described here faithfully recapitulates most clinical aspect of NASH including; marked steatosis, fibrosis, obesity, marked insulin resistance and dyslipidemia. This NASH animal model is validated with OCA which is a compound that has been shown to show clinical efficacy towards NASH.
- Saito, K, et al. Characterization of hepatic lipid profiles in a mouse model with nonalchoholic steatohepatitis and subsequent fibrosis. Sci Rep. 2015: 5:12466
- Cong WN, Tao RY, Tian JY, Liu GT, Ye F. The establishment of a novel nonalcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sciences 2008; 82:983–990
- Kleiner DE, Brunt EM, Natta MV, Behling C, Contos MJ, et.al. Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology, 2005; 41:1313–1321